Scarica l'app Stockscreener
19.94
0.86%
0.17
Dopo l'orario di chiusura:
20.07
0.13
+0.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$19.77
Aprire:
$19.55
Volume 24 ore:
2.67M
Relative Volume:
0.68
Capitalizzazione di mercato:
$4.35B
Reddito:
$10.68M
Utile/perdita netta:
$-272.71M
Rapporto P/E:
-12.74
EPS:
-1.565
Flusso di cassa netto:
$-213.38M
1 W Prestazione:
+6.18%
1M Prestazione:
-0.32%
6M Prestazione:
+121.80%
1 anno Prestazione:
+519.25%
Intervallo 1D:
$19.41
$20.71
Intervallo di 1 settimana:
$18.68
$20.71
Portata 52W:
$3.15
$20.79
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
19.94 | 4.06B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics Inc (RLAY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Institutional Confidence - TradingKey
Relay Therapeutics Inc (RLAY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RLAY|Relay Therapeutics Inc|Price:18.440|Chg%:-0.650 - TradingKey
Relay Therapeutics Inc (RLAY) Cash Flow - TradingKey
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
TradingKey - TradingKey
Relay Therapeutics Inc (RLAY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Relay Therapeutics Inc (RLAY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Relay Therapeutics Inc (RLAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise - Stock Titan
RLAY Maintained by Goldman Sachs -- Price Target Raised to $31 - GuruFocus
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Relay Therapeutics stock trades around recent lows as cash burn and pipeline data shape the outlook - Ad-hoc-news.de
Relay Therapeutics, Inc. SEC Filing (Jul 20, 2026) - Stock Titan
Certain Stock Options of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
Canaccord initiates Relay Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
Relay Therapeutics (RLAY) Edges Higher as Stock Tests Key Resistance at $20.68High Volume Stocks - dars.gov.et
Canaccord initiates Relay Therapeutics stock with buy rating - Investing.com
RLAY Initiated Coverage by Canaccord Genuity -- Price Target Ann - GuruFocus
CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29 - Moomoo
Relay Therapeutics Inc. (RLAY) Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Waits - Bölüm Sonu Canavarı
Relay Therapeutics president sells $162,028 in company stock - Investing.com UK
Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing - Moomoo
Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera - GuruFocus
Form 4 Relay Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock - Investing.com Nigeria
Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade - Stock Titan
Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics Insider Sold Shares Worth $943,736, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics president sells $162,028 in company stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings - Stock Titan
CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan - Stock Titan
Why Relay Therapeutics (RLAY) Is Up 5.5% After Broad Russell Growth Index Inclusion And What's Next - simplywall.st
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating By Investing.com - Investing.com Nigeria
JPMorgan initiates Relay Therapeutics stock coverage with overweight rating - Investing.com
Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com - Investing.com Nigeria
Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week high at 19.97 USD - Investing.com
Enterprise value to revenue forward of Relay Therapeutics, Inc. – NASDAQ:RLAY - TradingView
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.82%
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):